Inactive Instrument

All News Qiagen NV Nasdaq

Equities

AlphaValue/Baader Europe Upgrades Qiagen to Buy from Add, Lifts PT	Jul. 09	MT
QIAGEN to enhance the identification of human remains of Indigenous people and African Americans	Jul. 08	AQ
Qiagen to Enhance the Identification of Human Remains of Indigenous People and African Americans	Jul. 08	CI
QIAGEN N.V. to release results for Q2 2024 and hold webcast	Jul. 02	AQ
QIAGEN welcomes new U.S. guidelines for use of QuantiFERON-TB Gold Plus in detecting tuberculosis infections in children	Jun. 27	AQ
Qiagen N : AGM 2024 Voting Results	Jun. 27	PU
Wolfe Research Upgrades Qiagen to Outperform From Peer Perform, Price Target is $50	Jun. 27	MT
Qiagen Seeks M&A	Jun. 21	CI
Transcript : Qiagen N.V. - Shareholder/Analyst Call	Jun. 21
Qiagen N : Stifel – European Healthcare Summit Capital Markets Day Presentation	Jun. 20	PU
Qiagen N : Stifel – European Healthcare Summit Infographic	Jun. 20	PU
Sartorius on the downswing again - low since 2020 is approaching	Jun. 19	DP
Invest Securities Raises Qiagen PT, Maintains Neutral Rating	Jun. 19	MT
UBS Raises Qiagen Price Target to $46 From $44, Maintains Neutral Rating	Jun. 18	MT
JPMorgan Raises Price Target on Qiagen to $54 From $52, Maintains Overweight Rating	Jun. 18	MT
QIAGEN NV : Gets a Neutral rating from UBS	Jun. 18	ZD
QIAGEN NV : Deutsche Bank reaffirms its Buy rating	Jun. 18	ZD
QIAGEN NV : Berenberg remains its Buy rating	Jun. 18	ZD
Frankfurt shares close: Dax recovers	Jun. 17	DP
Transcript : Qiagen N.V. - Analyst/Investor Day	Jun. 17

No results for this search

QIAGEN : A decent start to 2024; guidance unchanged

April 30, 2024 at 09:32 am EDT